Wedbush Upgrades Sutro Biopharma to Outperform, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 93.8%

Neg 0% Neu 0% Pos 93.8%

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperform and raises the price target from $22 to $60.